Worldwide Industry for Hydroxychloroquine to 2027 - Repurposing Hydroxychloroquine as an Anti-Cancer Drug Presents Opportunities

News provided by

Jan 06, 2021, 09:45 ET

DUBLIN, Jan. 6, 2021 /PRNewswire/ -- The "Hydroxychloroquine Market by Product type, Distribution Channel, and Disease: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.

The global hydroxychloroquine market size was valued at $1.9 billion in 2019, and is anticipated to generate $4.6 billion by 2027. The market is projected to experience growth at a CAGR of 7.9% from 2020 to 2027.

Hydroxychloroquine, and anti-malarial drug, when combined with chloroquine has the potential to be the major game-changer in the medical history. In certain small and vitro, uncontrolled or poorly controlled clinical studies, it demonstrated antiviral activity against (SARS-CoV-2) severe acute respiratory syndrome-coronavirus-2. Such researches are considered as hypothesis. However, followed by the tweet of President Trump, it completely changed the scenario of the market, with reports of shortages of the medicine in pharmacies within 24 hours. Amidst the outbreak, certain nations such as the U.S. and India are endorsing its use as preventive measures for COVID-19.

The growth of the global hydroxychloroquine market is drive by surge in demand for the medication, which led to hike in production of the drug by the Indian Government. IPCA Laboratories, which have approximately 70% of the market share in this sector in India, has increased its production tenfold. However, the nationwide lockdown acted as a hindrance for growth of the global market. In addition, disruption in logistic chains and less availability of raw materials, which are mostly scoured from China have restrained the market growth. With the initiation of normal operation in China after the lockdown and backward integration of some industry players have helped the market to cope up to a certain extent.

In April 2019, IPCA Laboratories signed a contract to acquire Maharashtra-based Ramdev Chemical Pvt. Ltd. According to the contract, IPCA Laboratories is supposed to buy the company, which is associated with the marketing and manufacturing of advanced drug intermediates, active pharmaceutical ingredients (APIs), custom synthesis molecules, and fine chemicals. Thus, this initiative by IPCA Laboratories will help the company in increasing the production capacity of the drug and contribute in meeting the present demand.

On March 25 2020, the Indian Government imposed a ban on export of the drug to ensure that the nation had adequate stock of the medication to meet domestic needs. However, later the government decided to lift the ban partially. The SAARC nations along with other 30 nations and the U.S. and West Asia proposed India to lift the ban on export. Considering the high demand for the medication, pharmaceutical companies in the nation have planned to increase the production by 5 to 6 times to over 70 metric tons by May 2020. Apart from IPCA Laboratories Ltd., Zydus Cadila and Wallace Pharmaceuticals are some of the other leading manufacturers of hydroxychloroquine.

The global hydroxychloroquine market is segmented into product type, distribution channel, disease, and region. On the basis of product type, the market is bifurcated into tablet and active pharmaceutical ingredients. Depending on distribution channel, the market is fragmented into hospital pharmacy, online pharmacy, specialty drug store, and retail pharmacy. The diseases covered in the study include malaria, rheumatoid arthritis, lupus erythematosus, coronavirus, and others. Region wise, the hydroxychloroquine market analysis is done across North America, Europe, Asia-Pacific, and LAMEA (Latin America, Middle East, and Africa).

The key players operating in the hydroxychloroquine market are Cadila Healthcare Ltd., Hikma Pharmaceuticals PLC, Ipca Laboratories Ltd., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Taj Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Zydus Cadila. The companies have focused on various strategies such as new product launches, partnerships, acquisitions, and mergers for retaining their existing customer base and further increase their market share.

Key Benefits

The report provides extensive qualitative and quantitative analysis of the current trends and future estimations of the hydroxychloroquine market from 2019 to 2027 to determine the prevailing opportunities.
Comprehensive analysis of factors that drive and restrict hydroxychloroquine market growth is provided.
The hydroxychloroquine market forecast and estimations are based on factors impacting the market growth, in terms of value.
Profiles of leading players operating in the hydroxychloroquine market are provided to understand the global competitive scenario.
The report provides extensive qualitative insights on the significant segments and regions exhibiting favorable market share.

Key Topics Covered:

Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models

Chapter 2: Executive Summary
2.1. Key Findings of the Study
2.2. CXO Perspective

Chapter 3: Market Landscape
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Player Positioning
3.2.3. Porter's Five Forces Analysis
3.3. Patent Analysis
3.4. Value Chain Analysis
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Increase in Demand for Hcq as Potential Treatment Source Amidst Pandemic
3.5.1.2. Increase in Cases of Malaria
3.5.2. Restraint
3.5.2.1. Several Side-Effects of the Medicine
3.5.2.2. Ban from Several Countries Owing to Lacking Study Data
3.5.2.3. Ongoing Research and Positive Results of Other Drugs for Potential Cure
3.5.3. Opportunity
3.5.3.1. Repurposing Hydroxychloroquine as Anti-Cancer Drug
3.6. Impact of Corona (Covid 19) Outbreak on Global Hydroxychloroquine Market

Chapter 4: Hydroxychloroquine Market, by Product Type
4.1. Overview
4.1.1. Market Size and Forecast
4.2. Tablet
4.2.1. Key Market Trends, Growth Factors, and Opportunities
4.2.2. Market Size and Forecast, by Region
4.3. Active Pharmaceutical Ingredient
4.3.1. Key Market Trends, Growth Factors, and Opportunities
4.3.2. Market Size and Forecast, by Region

Chapter 5: Hydroxychloroquine Market, by Distribution Channel
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Hospital Pharmacy
5.2.1. Key Market Trends, Growth Factors, and Opportunities
5.2.2. Market Size and Forecast, by Region
5.3. Retail Pharmacy
5.3.1. Key Market Trends, Growth Factors, and Opportunities
5.3.2. Market Size and Forecast, by Region
5.4. Online Pharmacy
5.4.1. Key Market Trends, Growth Factors, and Opportunities
5.4.2. Market Size and Forecast, by Region
5.5. Specialty DrU.S.ore
5.5.1. Key Market Trends, Growth Factors, and Opportunities
5.5.2. Market Size and Forecast, by Region

Chapter 6: Hydroxychloroquine Market, by Diseases
6.1. Overview
6.1.1. Market Size and Forecast
6.2. Malaria
6.2.1. Key Market Trends, Growth Factors, and Opportunities
6.2.2. Market Size and Forecast, by Region
6.3. Rheumatoid Arthritis
6.3.1. Key Market Trends, Growth Factors, and Opportunities
6.3.2. Market Size and Forecast, by Region
6.4. Lupus Erythematosus
6.4.1. Key Market Trends, Growth Factors, and Opportunities
6.4.2. Market Size and Forecast, by Region
6.5. Coronavirus
6.5.1. Key Market Trends, Growth Factors, and Opportunities
6.5.2. Market Size and Forecast, by Region
6.6. Others
6.6.1. Key Market Trends, Growth Factors, and Opportunities
6.6.2. Market Size and Forecast, by Region

Chapter 7: Hydroxychloroquine Market, by Region
7.1. Overview
7.2. North America
7.3. Europe
7.4. Asia-Pacific
7.5. LAMEA

Chapter 8: Company Profiles:
8.1. Cadila Healthcare Limited
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Product Portfolio
8.1.4. Business Performance
8.2. Hikma Pharmaceuticals plc
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Product Portfolio
8.2.4. Business Performance
8.3. Ipca Laboratories Ltd.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Product Portfolio
8.3.4. Business Performance
8.3.5. Key Developmental Strategies
8.4. Mylan N. V.
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Product Portfolio
8.4.4. Business Performance
8.4.5. Key Developmental Strategies
8.5. Novartis International AG
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.6. Pfizer Inc.
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Product Portfolio
8.6.4. Business Performance
8.7. Sanofi S. A.
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Product Portfolio
8.7.4. Business Performance
8.8. Taj Pharma Group
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Product Portfolio
8.9. Teva Pharmaceutical Industries Ltd.
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Product Portfolio
8.9.4. Business Performance
8.10. Torrent Pharmaceuticals Limited
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Product Portfolio
8.10.4. Business Performance

For more information about this report visit https://www.researchandmarkets.com/r/nkxnz2

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets